Novel antibody-drug conjugates for triple negative breast cancer
Aiko Nagayama1, Neelima Vidula2, Leif Ellisen2
1Department of Surgery, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
Abstract:
Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody-drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
Insights
Antibody-drug conjugates (ADCs) show promise for treating aggressive triple-negative breast cancer (TNBC). This review discusses the development and clinical use of ADCs for advanced TNBC patients.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
- Antibody-drug conjugates (ADCs) are emerging as a targeted cancer therapy.
- ADCs combine monoclonal antibodies with cytotoxic payloads for targeted delivery.
Purpose of the Study:
- To review the development of ADCs for TNBC.
- To discuss the clinical application of ADCs in advanced TNBC.
- To highlight emerging ADC therapies in late-stage development.
Main Methods:
- Literature review of ADC development.
- Analysis of clinical trial data for ADCs in TNBC.
- Discussion of therapeutic strategies involving ADCs.
Main Results:
- Several ADCs are in late-stage clinical development for metastatic breast cancer, including TNBC.
- ADCs demonstrate potential in targeting and treating TNBC.
- Specific examples include sacituzumab govitecan and trastuzumab deruxtecan.
Conclusions:
- ADCs represent a significant advancement in TNBC treatment.
- Further clinical development is crucial for optimizing ADC therapy in TNBC.
- Targeted ADC therapies offer new hope for patients with advanced TNBC.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
